middle.news
Neuren’s Partner Acadia Expands US Access to DAYBUE STIX for Rett Syndrome
9:56am on Wednesday 8th of April, 2026 AEST
•
Healthcare
Read Story
Neuren’s Partner Acadia Expands US Access to DAYBUE STIX for Rett Syndrome
9:56am on Wednesday 8th of April, 2026 AEST
Key Points
DAYBUE STIX powder formulation now broadly available in US for Rett syndrome
FDA approval granted in December 2025, with initial limited launch in Q1 2026
Over 80% caregiver satisfaction reported in early feedback
Expert consensus supports trofinetide as part of standard care for Rett syndrome
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE